Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder, today announced the publication of a Hong Kong patent application covering innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress
Disorder and other mental health disorders.
The patent application is part of the Company's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
This morning’s news release says the compounds were invented by Professors Ahmed Masaewa, Rami Yaka, and Avi Priel of the Hebrew University. Under the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize the novel compounds.
The Hong Kong patent publication expands Clearmind's global patent application portfolio for its proprietary PTSD-focused psychedelic compounds. Together with existing international filings, the application supports the Company's strategy to seek intellectual property protection for its novel therapeutic candidates across major global markets.
According to market research by Heimdall Insights, the global PTSD therapeutics market was valued at approximately $19 billion in 2025 and is projected to reach $24.8 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 5.5%.
CMND shares closed Wednesday at $3.06.
Related Stories